Table of Contents
What changed
General Capital moved from loss to profit across the board in HY23. Net revenue rose 94.7% to NZ$3.5m from NZ$1.8m. PBT swung to NZ$1.5m from a loss of NZ$0.5m, and NPAT to NZ$1.0m from a loss of NZ$0.4m. The balance sheet expanded markedly: total assets up 52.7% to NZ$126.3m, total liabilities up 54.6% to NZ$111.8m, and equity up 39.8% to NZ$14.5m. Cash rose to NZ$17.2m from NZ$15.1m. No interim dividend was declared, consistent with the prior comparable period. Gross borrowings for HY23 and operating cash flow were not disclosed in the supplied data.
What matters
- Return to profit is broad-based, not tax-driven. The effective tax rate was steady at roughly 32.5% in both halves, so PBT growth (+390.7%) and NPAT growth (+390.6%) line up. The cleaner read is that underlying profitability genuinely flipped positive on scale.
- Segment mix is highly concentrated. Finance contributed ~95% of reported segment revenue and the only positive segment result (~NZ$1.5m on ~NZ$6.0m at an implied ~24% margin). Research & Advisory (~NZ$0.05m revenue, ~NZ$0.25m loss) and Corporate & Other (~NZ$0.25m revenue, ~NZ$0.11m loss) remain drags. The group's earnings quality is effectively a Finance-book story.
- Liabilities are growing faster than equity. Liabilities rose 54.6% while equity rose 39.8%. With term deposits ($71.4m at HY22) being the primary funding vehicle, the group is financing asset growth predominantly with deposit funding rather than retained earnings. Leverage ratios cannot be computed because HY23 gross borrowings and net debt were not disclosed.
Expectations
No quantified forward-work, deposit-book, or earnings target was disclosed. The only shape context available is that HY22 was a loss-making half of a profitable FY22 (HY22 NPAT was ‑27% of full-year NPAT), implying a 2H-weighted pattern in FY22. Against that anchor, HY23 net revenue annualises to roughly NZ$6.9m, or about 54% above FY22 reported revenue of NZ$4.5m. That establishes a meaningfully higher run-rate but says nothing about whether FY23 repeats the same 2H skew. The release does not support or refute a specific full-year profit shape.
Quality of result
The result looks scale-driven rather than timing-assisted. Revenue growth (+94.7%) matches the direction of asset growth (+52.7%), consistent with an expanding finance book earning a spread. Tax has not distorted the NPAT uplift. However, several quality checks are not possible from the supplied extract: operating cash flow, capex, free cash flow, and working-capital movements were not disclosed, so cash conversion cannot be tested; gross borrowings and net debt for HY23 were not disclosed, so leverage cannot be quantified; and no non-recurring items or non-GAAP adjustments were flagged. ROE improved to 8.3% from ‑3.6%, which is directionally supportive but off a small equity base. The absence of disclosed operating cash flow is the most notable gap for a lender-type entity where funding flows matter more than accrual profit.
Unresolved
- What is the HY23 deposit book and gross-borrowings balance, and has the deposit-to-equity ratio deepened alongside asset growth?
- What is operating cash flow, and does it corroborate the accrual swing to profit?
- Is the BB- credit rating referenced in prior periods unchanged, and are there any covenant or regulatory capital constraints near binding levels?
- What is management's plan for the loss-making Research & Advisory and Corporate & Other segments, given they absorb a meaningful share of Finance-segment profit?
- Are there concentration risks in the lending book that could become material as assets scale?
This briefing cannot assess cash generation, leverage trajectory, or valuation because operating cash flow, HY23 gross borrowings/net debt, and NTA per share were not disclosed in the supplied data.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $3450.8m | $1772.6m | +94.7% ↑ |
| Net profit after tax | $1038.7m | −$357.4m | +390.6% ↑ |
| Profit before tax | $1539.9m | −$529.7m | +390.7% ↑ |
| Cash and cash equivalents | $17240.0m | $15059.4m | +14.5% ↑ |
| Total assets | $126336.1m | $82718.2m | +52.7% ↑ |
Reference: annolyse.ai/briefings/gen-hy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Finance | $6015.3m | — | $1457.6m | n/a |
| Research and Advisory | $45.4m | — | −$247.5m | n/a |
| Corporate and Other | $252.1m | — | −$113.5m | n/a |
Reference: annolyse.ai/briefings/gen-hy23
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| Effective tax rate | 32.5% | n/m (loss period) | prior loss period |
| Gross borrowings | — | $71437.8m | — |
| Payout ratio vs NPAT | 0.0% | — | — |
| ROE (annualised) | 8.3% | -3.6% | Strengthening |
| HY22 share of FY22 revenue | 39.5% | — | Other half was 60.5% |
| HY22 share of FY22 NPAT | -26.7% | — | Other half was 126.7% |
Reference: annolyse.ai/briefings/gen-hy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.